A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

  • End date
    Jun 16, 2023
  • participants needed
  • sponsor
    MedImmune LLC
Updated on 4 April 2021


The purpose of this study is to evaluate MEDI5752 in combination with axitinib.in subjects with advanced renal cell carcinoma.


The purpose of this Phase 1b study is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of MEDI5752 in combination with axitinib in subjects with advanced renal cell carcinoma.

Condition Advanced Renal Cell Carcinoma
Treatment Axitinib, MEDI5752
Clinical Study IdentifierNCT04522323
SponsorMedImmune LLC
Last Modified on4 April 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note